Allergan Launches Juvéderm Volite
Allergan plc launched Juvéderm Volite, an injectable product specifically designed to improve skin quality and last up to nine months with just one treatment session. This innovative new Allergan product uses the unique patented Vycross technology.
The new HA injectable treatment delivers improvements in skin smoothness, hydration and elasticity, and is designed to last for up to nine months with just one treatment. Clinical data so far has shown significant improvements in skin quality for up to 6 months, and the clinical study is ongoing. Juvéderm Volite aims to deliver results that last and eliminate the need for multiple treatments. It should be injected intradermally and can be used to treat the face, neck, décolletage and hands and contains the anaesthetic lidocaine, to enhance patient comfort.
Dr Patricia Ogilvie, Leading Dermatologist, Germany, says: “Juvéderm® VOLITE answers a real need for a treatment that delivers a healthy-looking glow. Combined with the fact that only one treatment is needed to achieve results, this product will be a game changer in my clinic. I believe that great skin can have a profound impact on patients’ everyday lives – in particular their confidence. It goes far beyond aesthetics - when a patient is happy with how they look on the outside, this affects how they feel on the inside. Juvéderm® VOLITE is a genuinely innovative treatment option that I’m excited to be able to offer my patients.”
Juvéderm Volite delivers improvements on a range of skin quality components including smoothness (absence of fine lines), hydration and elasticity. In a clinical trial of 131 patients, the clinical study showed an improvement in skin quality at one, four and six months. One month after treatment, 96 percent of patients’ cheeks were smoother (investigator assessment) and 91 percent of patients reported they were more satisfied with their skin. Results were sustained at six months, where patients reported that they continued to see significant improvements in skin hydration and were satisfied with their skin. The final study results will be available in March 2017.
As with other medical aesthetic treatments, patients reported adverse events including bruising and pain at the injection site. However, Juvéderm Volite was well tolerated and demonstrated an acceptable safety profile, and 95 percent of patients were able to return to social engagements one day after treatment.
Caroline Van Hove, Senior Vice President, International Strategic Marketing for Medical Aesthetics at Allergan says: “The launch of Juvéderm® VOLITE defines Allergan’s disruptive entrance into the skin quality category - an area that we know is set to experience huge growth over the next few years, and with a product designed to last up to nine months with just one treatment. As a market leader, this demonstrates our ongoing commitment to delivering medical aesthetics treatments that physicians and their patients really want, that is convenient for patients and doctors, and of high quality in its results and safety.”